Clinical trial · Observational
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
A Randomized Cross-Over Study to Evaluate Patient Preference and Satisfaction With Urine-based Molecular Testing Versus Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample for biomarkers associated with disease recurrence. Cystoscopy is an examination of the bladder and urethra using a thin tube like instrument that is inserted into the urethra.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-muscle Invasive Bladder Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CxBladder Monitor | Diagnostic Test | — | UNRESOLVED |
| Cystoscopy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Arm A: CxBladder followed by cystoscopy
- description
- Arm A will undergo testing with CxBladder 3 months after randomization followed by a cystoscopy 3 months thereafter
- interventionNames
- Diagnostic Test: CxBladder Monitor
- Diagnostic Test: Cystoscopy
- label
- Arm B: cystoscopy followed by CxBladder
- description
- Arm B will undergo cystoscopy 3 months after randomization followed by testing with CxBladder 3 months thereafter.
- interventionNames
- Diagnostic Test: CxBladder Monitor
- Diagnostic Test: Cystoscopy
Primary outcomes (1)
- measure
- Preference for CxBladder Monitor compared to cystoscopy
- timeFrame
- Up to 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female with a history of histologically confirmed nonmuscle invasive bladder cancer (NMIBC) who have at least 6 months of disease-free survival from last recurrence. * Able to provide urine for testing and comply with study protocol. * Have an email address and be willing to complete surveys online. Exclusion Criteria: * History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma) * Patients with predominant (\>50%) variant histology * Patients with a history of upper tract and/or urethral cancer * Women who are pregnant
References
Publications (0)
Data not yet available